nicotinamide N-methyltransferase
Identifiers
EC no.2.1.1.1
CAS no.9029-74-7
Databases
IntEnzIntEnz view
BRENDABRENDA entry
ExPASyNiceZyme view
KEGGKEGG entry
MetaCycmetabolic pathway
PRIAMprofile
PDB structuresRCSB PDB PDBe PDBsum
Gene OntologyAmiGO / QuickGO
Search
PMCarticles
PubMedarticles
NCBIproteins

In enzymology, a nicotinamide N-methyltransferase (NNMT) (EC 2.1.1.1) is an enzyme that catalyzes the chemical reaction

S-adenosyl-L-methionine + nicotinamide S-adenosyl-L-homocysteine + 1-methylnicotinamide.

Thus, the two substrates of this enzyme are S-adenosyl methionine and nicotinamide, whereas its two products are S-adenosylhomocysteine and 1-methylnicotinamide.

This enzyme belongs to the family of transferases, specifically those transferring one-carbon group methyltransferases. The systematic name of this enzyme class is S-adenosyl-L-methionine:nicotinamide N-methyltransferase. This enzyme is also called nicotinamide methyltransferase.

Function

This enzyme participates in nicotinate and nicotinamide metabolism.

NNMT affects a biochemical mechanism known as a futile cycle, which plays a role in metabolic regulation. NNMT is found in human fat cells and the liver. NNMT processes vitamin B3 and has been linked with certain types of cancer. Silencing the gene that codes for NNMT reduces its presence and increases the presence of sugar transporter GLUT4.[1]

Mice that produced large amounts of GLUT4 were insulin sensitive and protected against diabetes, while mice with no GLUT4 were insulin resistant and at risk. High levels of NNMT are often found in the fat cells of animals that are insulin resistant. When the researchers silenced the NNMT gene in mice on high-fat diets, the mice gained less weight than those in whom the NNMT gene was functioning normally. (The mice did not change their eating or exercise habits).[1]

Antisense oligonucleotide (ASO) technology can be used to silence the expression of the NNMT gene only in fat and liver cells. ASOs are short strings of DNA that can be designed to prevent the synthesis of specific proteins. ASOs have been approved for use by the U.S. Food and Drug Administration for the treatment of conditions with other genetic causes—such as elevated cholesterol and hyperlipidemia.[1]

Structural studies

As of late 2007, two structures have been solved for this class of enzymes, with PDB accession codes 2I62 and 2IIP.

References

  1. 1 2 3 "Slow metabolism hindering weight loss? Genetic 'switch' may be answer". Fox News. 2006-10-01. Retrieved 2014-04-11.
  • Cantoni GL (March 1951). "Methylation of nicotinamide with soluble enzyme system from rat liver". The Journal of Biological Chemistry. 189 (1): 203–16. PMID 14832232.


This article is issued from Wikipedia. The text is licensed under Creative Commons - Attribution - Sharealike. Additional terms may apply for the media files.